CME/CE Accreditation Information Return to Previous

Managing Prurigo Nodularis - Latest Advances and Strategies

1. Describe the pathogenesis of prurigo nodularis (PN).
2. Implement strategies to appropriately evaluate and timely diagnose patients with PN.
3. Summarize the impact of PN on patients’ quality-of-life.
4. Apply current evidence-based approaches and therapies to individualize treatment for patients with PN.


This activity was launched on November 10, 2023 and will expire on November 10, 2024.

This educational initiative has been designed for dermatology physicians, nurse practitioners, and physician assistants involved in the management of patients with PN.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

Horizon CME designates this enduring material for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


•    Read the learning objectives and faculty disclosures.
•    Participate in the activity.
•    Complete the post-test and activity evaluation.
•    Physicians who successfully complete the post-test and evaluation will receive CME credit.
•    All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity. 


Gil Yosipovitch, MD
Miami Itch Center, Phillip Frost Department of Dermatology and Cutaneous Surgery
Miller School of Medicine
University of Miami
Miami, Florida
Dr. Yosipovitch discloses that he is on an advisory board for AbbVie, Arcutis, CARA, Galderma, Incyte and Sanofi Regeneron and Vifor as well as a consultant for AbbVie, CARA, Escient, Galderma, Pfizer, Sanofi Regeneron and Vifor. He also is an investigator and/or receives grant support from AbbVie, Arcutis, CARA, Escient, Galderma, Incyte, Pfizer, Sanofi Regeneron and Vifor. Dr. Yosipovitch is on a committee for Pfizer, during the past 24 months.

Timothy Berger, MD
Professor Emeritus of Clinical Dermatology
University of California San Francisco
San Francisco, CA

Dr. Berger discloses he is on a speaker’s bureau for Sanofi-Regeneron, during the past 24 months.

Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

This activity is supported by an independent educational grant from Sanofi and Regeneron Pharmaceuticals.